Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23599472 | 0.93 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2798328 | 0.89 | MEN1 (0.53) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29572349 | 0.89 | MEN1 (0.53) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18838469 | 0.88 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18838292 | 0.88 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2798935 | 0.88 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL18838470 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL28903930 | 0.85 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL30803180 | 0.85 | CYP2D6 (0.49) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18838468 | 0.85 | MEN1 (0.56) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292110-B1 | N-PIPERIDIN-4-YL DERIVATIVES | MERCK SHARP & DOHME (NL) | 2019-08-21 | — | — | EP | disclosed |
| EP-2734529-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-8993757-B2 | N-piperidin-4-yl derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-03-31 | — | — | US | disclosed |
| US-20140329822-A1 | N-PIPERIDIN-4-YL DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2014-11-06 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| EP-2734529-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-2548877-A1 | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors | MSD Oss B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | SMN1; SMN2 3846/4885NPC1 3286/4885RAB9A 1303/4885 |
| US-20140329822-A1 | N-PIPERIDIN-4-YL DERIVATIVES | PGR, CYP19A1, BRCA1 | SMN1; SMN2 2841/4885NPC1 2207/4885RAB9A 1611/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | SMN1; SMN2 3577/4885NPC1 3341/4885RAB9A 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.